Amneal Pharmaceuticals (AMRX) Cash & Equivalents (2017 - 2026)

Amneal Pharmaceuticals' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 36.59% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (down 36.59% YoY), while the FY2025 annual figure was $282.0 million, up 155.11% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $4.2 million, down from $282.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $282.0 million in Q4 2025, with the low at $4.2 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $9.6 million (2025), against an average of $54.5 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 97.77% in 2022, then soared 2284.21% in 2023.
• Amneal Pharmaceuticals' Cash & Equivalents stood at $9.3 million in 2022, then surged by 889.54% to $91.5 million in 2023, then increased by 20.77% to $110.6 million in 2024, then jumped by 155.11% to $282.0 million in 2025, then plunged by 98.52% to $4.2 million in 2026.
• Business Quant data shows AMRX's Cash & Equivalents at $4.2 million in Q1 2026, $282.0 million in Q4 2025, and $34.7 million in Q3 2025.